Effect of Homoharringtonine on Bone Morrow CD34^+CD7^+ Cells in Chronic Granulocytic Leukemia

Objective： To explore the effect of homoharringtonine （HHT） on bone morrow CD34^＋CD7^＋ cells in chronic granulocytic leukemia （CGL）. Methods： The changes of bone morrow CD34^＋CD7^＋ cells were observed after the treatment of HHT in 23 cases with CGL. The proliferation and apoptosis of CD34^＋CD7^＋ cells treated with HHT in vitro were studied. Results： The proportion of CD34^＋CD7^＋ cells in CGL （0.145±0.021） was higher than that of normal control （0.052±0.013）. The proportion of CD34^＋CD7^＋ cells in patients who got cytogenetic responses to HHT （0.072±0.020） decreased remarkably, but not in those patients who did not got cytogenetic responses to HHT, （0.137±0.023）. the proliferation of CD34^＋ cells was inhibited and the proportion of CD34^＋CD7^＋ cells decreased after cultured with HHT （0.134 in 24 h, 0.126 in 48 h and 0.102 in 72）. The apoptosis rate of CD34^＋CD7^＋ cells was higher than that in CD34^＋CDT cells （35.39%±4.39% versus 24.57%±4.01%, P〈0.05） 72 h after culture with HHT. Conclusion： The proportion of CD34^＋CD7^＋ cells in CGL was higher than that of normal control and HHT may inhibit the proliferation and induce apoptosis of bone marrow CD34^＋CD7^＋ cells.

肿瘤患者外周血干细胞动员过程中CD_(34)^+细胞的动态变化及意义

为观察肿瘤患者 CD+ 34 细胞数量在动员过程中的动态变化 ,确定采集干 /祖细胞的最佳时机 ,采用环磷酰胺 (CTX)联合粒细胞集落刺激因子 (G- CSF)对 2 1例肿瘤患者进行造血干 /祖细胞动员。动员过程中 ,每天进行血细胞计数 ,于前期、极期、恢复早期、恢复期计数外周血 CD+ 34 细胞、白细胞 (WBC)、单核细胞 (MNC)、血小板(Plt)。结果显示 ,不同患者出现极期、恢复早期、恢复期的时间差异较大。与前期相比 ,极期 CD+ 34 明显降低(P<0 .0 5 ) ,恢复期则显著增加 (P<0 .0 1)。WBC、MNC、Plt变化均与 CD+ 34 细胞变化呈显著正相关 (r分别为 0 .99、0 .82 7、0 .886 ,P均 <0 .0 1)。提示在 WBC>5 .0× 10 9/ L时采集外周血造血干细胞 (PBSC)较合适 ,MNC>1.5×10 9/ L时采集 PBSC较理想 ,监测 Plt计数变化 。

Radix Ilicis Pubescentis total flavonoids combined with mobilization of bone marrow stem cells to protect against cerebral ischemia/reperfusion injury

Previous studies have shown that Radix Ilicis Pubescentis total flavonoids have a neuroprotective effect, but it remains unclear whether Radix Ilicis Pubescentis total flavonoids have a synergistic effect with the recombinant human granulocyte colony stimulating factor-mobilized bone marrow stem cell transplantation on cerebral ischemia/reperfusion injury. Rat ischemia models were administered 0.3, 0.15 and 0.075 g/kg Radix Ilicis Pubescentis total flavonoids from 3 days before modeling to 2 days after injury. Results showed that Radix Ilicis Pubescentis total flavonoids could reduce pathological injury in rats with cerebral ischemia/reperfusion injury. The number of Nissl bodies increased, Bax protein expression decreased, Bcl-2 protein expression increased and the number of CD34-positive cells increased. Therefore, Radix Ilicis Pubescentis total flavonoids can improve the bone marrow stem cell mobilization effect, enhance the anti-apoptotic ability of nerve cells, and have a neuroprotective effect on cerebral ischemia/reperfusion injury in rats.

Exploring hematopoietic stem cell population in human milk and its benefits for infants:A scoping review

Objective:To comprehensively explore hematopoietic stem cells(HSCs)in human milk,understanding their molecular markers,isolation methods,benefits for infants,and potential medical applications.Methods:We conducted a scoping literature review following the PRISMA-ScR guidelines.This review included studies investigating HSCs in human milk,utilizing molecular markers such as CD34^(+),CD113^(+),and CD117^(+)for characterization.Both in vitro and in vivo studies exploring the morphology,function,and clinical implications of these cells were considered.The diverse range of papers reviewed were indexed in PubMed,Science Direct,Scopus,Sage Journals,and Google Scholar,published between 2010 and 2023.Results:This scoping review explored 577 articles and selected 13 studies based on our inclusion criteria,focusing on HSCs in human milk.Most studies dilute samples prior to HSC isolation,followed by detection using markers such as CD34^(+),CD113^(+),and CD117^(+),with flow cytometry serving as the primary analysis tool,focusing on their isolation and detection methods.While no definitive benefits have been conclusively established,there is a strong belief in the potential of HSCs to positively impact infant immunity,growth,and tissue repair.Conclusions:This review presents significant evidence supporting the presence of HSCs in human milk,identified by markers such as CD34^(+),CD113^(+),and CD117^(+).These cells show considerable potential in enhancing infant health,including immunity,tissue repair,cognitive development,and gastrointestinal health.Despite methodological variations in isolation and detection techniques,the collective findings underscore the potential clinical relevance of HSCs in human milk.Moreover,this review highlights the noninvasive accessibility of human milk as a source of HSCs and emphasizes the need for further research to unlock their therapeutic potential.

Negative association of donor age with CD34＋ cell dose in mixture allografts of G-CSF-primed bone marrow and G-CSF-mobilized peripheral blood harvests

Background The effects of donor characteristics on CD34＋ cell dose remain controversial. Recently, we developed a novel haploidentical transplant protocol, in which mixture allografts of granulocyte colony-stimulating factor （G-CSF）- primed bone marrow （G-BM） and G-CSF-mobilized peripheral blood （G-PB） were used. The aim of this study was to investigate the effects of donor characteristics on CD34＋ cell dose in mixture allografts of G-BM and G-PB. Methods A total of 162 healthy adult donors, who underwent bone marrow harvest and peripheral blood collection between January 2009 and November 2010 in Peking University People＇s Hospital, were prospectively investigated. G-CSF was administered subcutaneously at a dose of 5 pg/kg once a day for 5-6 consecutive days. Bone marrow and peripheral blood stem cells were harvested on the fourth day and fifth day, respectively. A final total CD34＋ cell dose less than 2× 106 cells/kg recipient body weight was considered a poor mobilization. Results Of the 162 donors, 31 （19.1%） did not attain this threshold. The obtained median CD34＋ cell doses in bone marrow, peripheral blood, and mixture allografts were 0.83×106/kg, 2.40×106/kg, and 3.47×106/kg, respectively. Multiple regression analysis showed that donor age had a significant negative effect on CD34＋ cell dose in either G-BM, or G-PB, or mixture allografts of G-BM and G-PB. And a 1-year increase in age was associated with a 5.6% decrease in the odds of achieving mobilization cutoff. No significant correlation was found for donor gender, body mass index （BMI）, and weight. Conclusion Donor age is the only factor among the four parameters, including age, gender, weight, and BMI, that influence CD34＋ cell dose in mixture allografts of G-BM and G-PB, and younger donors should be chosen to obtain sufficient CD34＋ cells for transplantation.

Effect of intracranial transplantation of CD34^+ cells derived from human umbilical cord blood in rats with cerebral ischemia

As a source of transplantable stem cells, the CD34^＋ subpopulation in human umbilical cord blood （HUCB） has been used extensively to treat some hematopoietic system diseases. However, whether CD34^＋ cells hold the therapeutic potential to cerebral ischemia is unknown. The purpose of this study was to observe the recovery of neural function after transplantation of CD34^＋ cells derived from HUCB into ischemic cerebral tissue in rats.

Characteristics of Ex Vivo Expansion of Endothelial Progenitor Cells

Summary： The characteristics for the ex vivo expansion of the endothelial progenitor cells （EPCs） were explored, CD34^＋ cells were selected from umbilical cord blood mononuclear cells （MNC） by MiniMACS system, expanded under the same conditions as those for total MNC, coincubation of CD34^＋ and CD34 from the same donor for EPCs. In addition, the effects of vessel endothelial growth factor （VEGF） and passage on cell differentiation, expansion kinetics and apoptosis were examined, EPCs were determined and quantified by immunocytochemistry and flow cytometry, The results showed that both coculture of CD346＋ and CD34^- and total MNC led to a significant increase in the expansion of CD34^＋ cells as compared with CD34 enrichment （P〈0.05）. There was a tendency toward decreased apoptosis in cultures when early passage was performed immediately after cord like structures appeared. VEGF had no significant effect on apoptosis （P〉0.05）, These differentiated EPCs were positive for CD34^＋, von Willebrand factor （vWF）, KDR, CD31 staining and phagocytized acetylated low-density lipoprotein （LDL）. CD34^＋ cells accounted for （68.2±6,3） % of attaching （AT） cells at day 7 of culture. It was suggested the most efficient method to ex vivo expansion of EPCs was coculture of CD34^＋ and CD34^- or total MNC. Early passage makes cell apoptosis rate decrease. VEGF had no significant effect on ex vivo expansion of EPCs.

Retroviral transduction of a mutant erbB-2 gene into human CD34^+ derived dendritic cells

Objective To successfully transduce a mutant erbB 2 gene into normal human CD34 + derived dendritic cells (DCs) and verify gene expression in these transduced dendritic cells Methods The packaging cell line PA317 was transfected with mutant erbB 2 gene DNA and the virus produced was used to infect packaging cell line PG13 The virus produced by PG13 was used to infect CD34 + derived dendritic cells by the spinoculation method using flasks coated with fibronectin material to facilitate retrovirus gene transter efficiency and the mutant erbB 2 gene expression was assessed by ABC staining and FACScan methods Results A mutant erbB 2 gene packaging cell line was produced and this mutant gene was transduced into human CD34 + derived DCs It was verified that the relatively large numbers of the transduced DCs expressed the mutant erbB 2 protein which was eradicated of the ability to transform mouse NIH3T3 fibroblast cells Conclusions Human DCs can be gene modified and these gene modified DCs may be useful in stimulating T lymphocytes for immunotherapy

Clinical significance of CD34^(+)CD117^(dim)/CD34^(+)CD117^(bri) myeloblast-associated gene expression in t(8;21)acute myeloid leukemia

OriginalTranslation t(8;21)(q22;q22)acute myeloid leukemia(AML)is a highly heterogeneous hematological malignancy with a high relapse rate in China.Two leukemic myeloblast populations(CD34^(+)CD117^(dim) and CD34^(+)CD117^(bri))were previously identified in t(8;21)AML,and CD34^(+)CD117^(dim) cell proportion was determined as an independent factor for this disease outcome.Here,we examined the impact of CD34^(+)CD117^(dim)/CD34^(+)CD117^(bri) myeloblast-associated gene expression on t(8;21)AML clinical prognosis.In this study,85 patients with t(8;21)AML were enrolled.The mRNA expression levels of CD34^(+)CD117^(dim)-associated genes(LGALS1,EMP3,and CRIP1)and CD34^(+)CD117^(bri)-associated genes(TRH,PLAC8,and IGLL1)were measured using quantitative reverse transcription PCR.Associations between gene expression and clinical outcomes were determined using Cox regression models.Results showed that patients with high LGALS1,EMP3,or CRIP1 expression had significantly inferior overall survival(OS),whereas those with high TRH or PLAC8 expression showed relatively favorable prognosis.Univariate analysis revealed that CD19,CD34^(+)CD117^(dim) proportion,KIT mutation,minimal residual disease(MRD),and expression levels of LGALS1,EMP3,CRIP1,TRH and PLAC8 were associated with OS.Multivariate analysis indicated that KIT mutation,MRD and CRIP1 and TRH expression levels were independent prognostic variables for OS.Identifying the clinical relevance of CD34^(+)CD117^(dim)/CD34^(+)CD117^(bri) myeloblast-associated gene expression may provide new clinically prognostic markers for t(8;21)AML.

骨髓增生异常综合征患者骨髓凋亡细胞类型及TRAIL表达水平研究

目的探讨骨髓增生异常综合征(MDS)患者骨髓细胞凋亡累及的细胞类型,以及其与肿瘤坏死因子相关凋亡诱导配体(TRAIL)表达水平的关系。方法用流式细胞术检测骨髓有核细胞总凋亡率、CD3+、CD3+4细胞凋亡率和TRAIL表达水平,运用CellQuest及ModFit软件对所测得结果进行数据分析。结果MDS患者骨髓有核细胞总凋亡率为(17.39±10.17)%,CD+3、CD3+4细胞凋亡率分别为(20.41±11.61)%、(21.32±12.17)%,TRAIL表达水平为(7.55±3.10)%,均显著高于正常对照组[(5.88±1.38)%、(5.47±1.65)%、(4.92±2.11)%、(1.26±0.46%)],P<0.05。早期MDS有核细胞总凋亡率为(21.95±9.44)%、TRAIL表达水平为(9.00±2.47)%,均高于进展期[(8.26±2.27)%、(4.65±2.04)%],P<0.05。骨髓有核细胞总凋亡率与骨髓原始细胞数呈负相关(r=-0.65,P<0.05),与TRAIL表达水平呈正相关(r=0.85,P<0.05)。结论MDS存在过度凋亡,凋亡累及早期造血细胞和淋巴细胞;TRAIL可能是引起凋亡增加的原因之一。

化疗+G-CSF方法动员外周血干细胞时骨髓及外周血相关细胞亚群的动态变化(英文)

目的 探讨应用化疗 +G -CSF方法动员外周血干细胞时 ,恶性血液病患者的骨髓及外周血CD3 4 +细胞和T细胞亚群的变化特点。方法 16例拟行自体外周血干细胞移植患者 ,在应用化疗 +G -CSF方法动员外周血干细胞期间 ,应用流式细胞仪测定骨髓及外周血CD3 4 + 和T细胞亚群动态变化情况。结果 1.恶性血液病患者在应用G -CSF前 ,骨髓中CD3 4 + 细胞的初始值为 (0 .5 2± 0 .31) %。应用G -CSF 4 8h后 ,CD3 4 + 细胞测定值为 (1.2 2± 0 .4 2 ) % ,较前有明显增加 (P <0 .0 0 1)。CD3 4 + 细胞的高峰值出现在应用G -CSF 96h后 ,为 (2 .2 3± 0 .34) % ,较未应用G -CSF时差异显著 (P <0 .0 0 1)。 2 .恶性血液病患者在应用G -CSF前 ,外周血CD3 4 + 细胞测定值为 (0 .39± 0 .2 7) %。在应用G -CSF 72h后外周血中CD3 4 + 细胞的测定值为 (1.2 9± 0 .6 4 ) % ,较前有明显增加 (P <0 .0 0 1)。应用G -CSF96h后 ,CD3 4 + 细胞的测定值达高峰 ,为 (1.4 1± 0 .73) % ,较未应用G -CSF前差异显著 (P <0 .0 0 1)。 3.无论是否应用G -CSF ,恶性血液病患者的T淋巴细胞亚群比例均处于倒置状态 ,应用G -CSF后随CD3 4 + 细胞的逐渐增加 ,T淋巴细胞亚群变化不明显 (P >0 .0 5 )。结论 恶性血液病患者 ,在应用化疗 +G -CSF?

终末期肾病中循环内皮祖细胞的变化及其意义

内皮祖细胞（endothelial progenitor cells,EPCs）是血管内皮细胞的前体细胞,具有较强的增殖分化能力,能分化为成熟的血管内皮细胞。1997年Asahara等首次从外周血单个核细胞分离得到CD34^＋细胞，进而在体外诱导成血管内皮细胞，证实外周血液循环中存在内皮祖细胞；此后对循环内皮祖细胞（circulating endothelial progenitor cells，CEPCs）进一步研究发现CEPCs对保护和修复血管内皮层有重要作用，

内皮祖细胞及其在血管组织工程中的应用

内皮祖细胞（endothelial progenitor cells，EPCs）是指能从骨髓迁移到外周血，并分化为血管内皮细胞的祖细胞，又称血管内皮干细胞（endothelial stem cells）。1997年Asahara等^[1]。应用免疫磁珠法从成人外周血中分离CD34^＋细胞，并在预衬纤维连接蛋白（fibronectin，Fn）的培养皿培养，

树突细胞前体可受登革病毒和人类免疫缺陷病毒感染

黏膜表面、皮肤和血液中的树突细胞（dendritic cells，DC）由于能在这些部位摄取抗原，易成为病毒感染的初始靶细胞。含有Birbeek颗粒的CDl4^＋细胞亚群能分化成朗格汉斯型DC，表明了这些亚型是DC的前体。这些CDl4^＋细胞具有髓样DC前体的特性，能表达凝集因子XⅢa或C型凝集素（lectin）DC，SIGN等特异性表面标志。通过加入单核细胞集落刺激因子（M-CSF）对CD34^＋前体细胞进行培养可以获得CDl4^＋亚群，